BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.
The company reported that it signed agreements for 337 instruments , while revenue-generating placements totaled 78 across the US, European, and Middle East regions.
New Medicare rates established under PAMA will cause labs to scale back services, and in some cases shut down, the motion states.
TearLab sought a permanent injunction in Canada to keep I-Med's I-Pen Osmolarity System off the market, the company said.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.
The Class III Medical Device System License enables an early-risk assessment of the most common fetal genetic abnormalities in the first trimester of pregnancy.
The company offers a range of tumor profiling products including the OncoDeep solid tumor test and the OncoTrace liquid biopsy test.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
The firm cited "strong demand for pathology products and companion diagnostics services" for revenue gains in its Diagnostics and Genomics Group.
The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood.
The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.
The immunoassay allows for the rapid detection of influenza types A and B antigens directly in nasal swab and nasopharyngeal swab specimens from symptomatic patients.
The company issued more than 1.8 million shares of its common stock to several of its trade creditors to erase debt that it owed them, Precipio said in an SEC document.
The five-year federal supply contract is for the company's Steripath Initial Specimen Diversion Device, which virtually eliminates blood culture contamination.
OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.
Currently available screening methods have not been shown to reduce mortality in the general population, USPSTF said.
The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.
A meta-analysis concluded that combining a biomarker blood test with ultrasound increased the detection of early-stage liver cancer by as much as 40 percent.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.